Inhibition of Leishmania mexicana growth by the tuberculosis drug SQ109

Verónica García-García, Eric Oldfield, Gustavo Benaim

Research output: Contribution to journalArticlepeer-review


We report that the tuberculosis drug SQ109 [N-adamantan-2-yl-N′-((E)-3,7-dimethyl-octa-2,6-dienyl)-ethane-1,2-diamine] has potent activity against the intracellular amastigote form of Leishmania mexicana (50% inhibitory concentration [IC50], ∼11 nM), with a good selectivity index (>500). It is also active against promastigotes (IC50, ∼500 nM) and acts as a protonophore uncoupler, in addition to disrupting Ca2+ homeostasis by releasing organelle Ca2+ into the cytoplasm, and as such, it is an interesting new leishmaniasis drug hit candidate.

Original languageEnglish (US)
Pages (from-to)6386-6389
Number of pages4
JournalAntimicrobial Agents and Chemotherapy
Issue number10
StatePublished - Oct 2016

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Inhibition of Leishmania mexicana growth by the tuberculosis drug SQ109'. Together they form a unique fingerprint.

Cite this